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The activation NKG2D receptor has been shown to play an important role in the control of 
experimental tumor growth and metastases expressing ligands for NKG2D; however, a 
function for this recognition pathway in host protection from de novo tumorigenesis has 
never been demonstrated. We show that neutralization of NKG2D enhances the sensitivity 
of wild-type (WT) C57BL/6 and BALB/c mice to methylcholanthrene (MCA)-induced 
fibrosarcoma. The importance of the NKG2D pathway was additionally illustrated in mice 
deficient for either IFN-
 
 
 
 or tumor necrosis factor–related apoptosis-inducing ligand, 
whereas mice depleted of natural killer cells, T cells, or deficient for perforin did not display 
any detectable NKG2D phenotype. Furthermore, IL-12 therapy preventing MCA-induced 
sarcoma formation was also largely dependent on the NKG2D pathway. Although NKG2D 
ligand expression was variable or absent on sarcomas emerging in WT mice, sarcomas 
derived from perforin-deficient mice were Rae-1
 
 
 
 and immunogenic when transferred into 
WT syngeneic mice. These findings suggest an important early role for the NKG2D in 
controlling and shaping tumor formation.
 
NKG2D is a key homodimeric activation re-
ceptor expressed on the cell surface of almost
all NK cells, 
 
  
 
 cells, some cytolytic CD8
 
 
 
 
 
  
 
T cells and NKT cells, and a small subset of
CD4
 
 
 
 
 
  
 
 T cells (1–5). Several ligands that
bind to NKG2D are members of the MHC
class Ib family (5, 6). In humans, the polymor-
phic MHC class I chain–related molecules
(MIC) A and MICB can be recognized by
NKG2D (3, 7). Although MIC molecules
have not been found in mice, the 
 
retinoic acid
early inducible-1
 
 (
 
Rae-1
 
) gene products UL16-
binding protein-like transcript 1 (Mult1) and a
distantly related minor histocompatibility Ag,
H60, have been reported as NKG2D ligands
in mice (5, 6, 8, 9).
The immune system responds to “stressed
self,” and stress signals include molecules released
by dying cells such as putative endogenous
ligands for TLRs (10, 11), uric acid (12), and
surface molecules, including MHC Class Ib
gene products, that are up-regulated by heat
shock, retinoic acid, IFN-
 
 
 
, TLR signaling,
growth factors, viral infection, DNA damage,
and UV irradiation (13–17). In particular, un-
like conventional MHC class I, the MHC class
Ib MIC proteins display up-regulated surface
expression on stressed cells and are frequently
overexpressed by tumors that are reportedly in-
filtrated by larger numbers of lymphocytes than
are MIC
 
 
 
 tumors (18, 19). In the mouse, the
expression of the MHC Class Ib molecules,
Rae-1, and H60 is negligible in normal skin
but is strongly induced by skin painting with
chemical carcinogens (20). Natural or induced
expression of NKG2D ligands markedly en-
hances the sensitivity of tumor cells to NK cells
in vitro (2–5, 8, 21). Expression of NKG2D
ligands by tumor cells also results in immune
destruction in vivo, and the ectopic expression
of NKG2D ligands, Rae-1, and H60 in several
tumor cell lines results in the rejection of the
tumor cells expressing normal levels of MHC
class I molecules (6, 22). Immune depletion
and other experiments showed that rejection
was dependent on NK cells and/or CD8
 
 
 
 T
cells and perforin (22, 23). Our more recent
study has illustrated that some cytokines mediate
their antitumor activity, largely via the NKG2D–
NKG2D ligand pathway (24).
However, despite the assumption that
NKG2D-mediated engagement of stress-induced
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ligands may be a key aspect of tumor immune surveillance (20,
25), no study has ever evaluated the importance of the pathway
in de novo tumorigenesis. We show the importance of the
NKG2D activation receptor in controlling the natural and acti-
vated host response to spontaneous malignancy.
 
RESULTS AND DISCUSSION
NKG2D neutralization enhances methylcholanthrene 
(MCA)-induced sarcoma formation in mice
 
Neutralizing anti-NKG2D mAbs have the ability to enhance
the growth and metastasis of tumors that ectopically or en-
dogenously express NKG2D ligands (22, 23). To evaluate
the importance of the NKG2D pathway in de novo tumori-
genesis, B6 mice were inoculated with increasing doses of
MCA and treated for 8 wk with control or anti-NKG2D
mAb (Fig. 1 A). At all MCA doses examined, mice treated
with anti-NKG2D mAb had a greater incidence of fibrosar-
coma than control Ig–treated mice. Similar increased inci-
dence was obtained when treating mice for more extended
periods of time with anti-NKG2D mAb (day 0–140; unpub-
lished data). Sarcoma formation was also assessed in BALB/c
mice inoculated with MCA. In concert with the findings in
B6 mice, neutralization of NKG2D increased sarcoma for-
mation in BALB/c mice (Fig. 1 B). Thus, in two different
strains of mice, the activation receptor NKG2D controls the
initiation of MCA-induced sarcoma.
 
The NKG2D pathway is perforin mediated and only partially 
responsible for host protection from sarcoma by NK cells 
or T cells
 
To determine whether NKG2D neutralization could ac-
count for all host NK cell– and T cell–mediated protection
from MCA sarcoma, B6 RAG-1
 
   
 
 and B6 WT mice de-
pleted of NK cells were additionally treated with control or
anti-NKG2D mAbs. At a dose of 25 
 
 
 
g MCA, both WT
mice depleted of NK cells and RAG-1
 
   
 
 mice had a similar
time of onset and number of sarcomas when treated with
anti-NKG2D compared with control Ig (Fig. 2 A). Similar
data was obtained at lower doses of MCA (Fig. S1, available
at http://www.jem.org/cgi/content/full/jem.20050994/
DC1). In each case, both WT mice depleted of NK cells and
RAG-1
 
   
 
 mice also demonstrated more sarcomas than WT
mice neutralized with anti-NKG2D (Fig. 2 A and Fig. S1).
Because control of MCA-induced sarcoma is mediated by a
combination of perforin, TRAIL, and IFN-
 
  
 
effector mole-
cules, we next examined whether NKG2D neutralization in
mice deficient in each of these pathways was effective (Fig. 2
B). Clearly, the importance of the NKG2D pathway was ad-
ditionally illustrated in mice deficient for either IFN-
 
 
 
 or
TRAIL, whereas mice deficient for perforin did not display
any detectable NKG2D phenotype. A very similar pattern of
response was also observed at lower doses of carcinogen (un-
published data). These data suggest that the NKG2D path-
way was operating primarily to activate host perforin-medi-
ated cytotoxicity.
 
Established MCA-induced sarcomas do not generally express 
the Rae-1 NKG2D ligands
 
Given the potential of the immune system to edit tumors, in-
cluding sarcomas (26, 27), it might be expected that various
gene-targeted mice might have an increased proportion of
tumors displaying an unedited phenotype and expressing
Rae-1. We derived fibrosarcoma cell lines from several WT
and gene-targeted mice treated with MCA (Fig. 3 A and not
depicted). Evaluation of up to 16 sarcomas derived from WT
mice demonstrated Rae-1. expression was variable (6/16, 3
high and 3 low) or absent (10/16), and similar frequencies
were observed in sarcomas derived from TRAIL
 
   
 
 mice
(5/8 negative for Rae-1; Fig. 3 A). In contrast, sarcomas de-
rived from perforin-deficient mice were shown to universally
Figure 1. NKG2D neutralization enhances MCA initiation of sarcoma. 
Groups of 10 B6 WT (A) or BALB/c WT (B) mice were injected s.c. into the 
hind flank with 1–100  g MCA as indicated. Mice were treated i.p. twice 
weekly from day 0 (the day of MCA inoculation) with 250  g of control Ig 
(cIg) or anti-NKG2D mAb for 8 wk. Palpable sarcomas ( 10 mm2) were 
recorded, and tumor-free mice were monitored for 200 d. The asterisks 
denote a significant effect of anti-NKG2D as determined by Fisher’s exact 
test (P   0.05). 
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express medium to high levels of Rae-1 (7/7; Fig. 3 A). In-
terestingly, when the Rae-1
 
 
 
 sarcomas were injected at low
doses into WT recipients, their growth was retarded in a host
NKG2D- and perforin-dependent manner (Fig. 3 B). Not
surprisingly, the growth of Rae-1
 
 
 
 sarcomas from WT or
TRAIL
 
   
 
 mice was similar in WT and pfp
 
   
 
 mice and un-
affected by NKG2D neutralization (Fig. 3 B). Therefore, it is
possible that the NKG2D–NKG2D ligand pathway only
plays a tumor suppressive role very early in the host response
to transformation. Once established, some tumors may ex-
press NKG2D ligands and yet continue to grow, perhaps by
inducing immune suppression by directly down-modulating
NKG2D on local immune effector cells or by other means of
tumor escape. In a similar manner, it will now be important
to completely evaluate Rae-1 expression on sarcomas derived
from WT mice neutralized for NKG2D and H60 on all sar-
comas derived from BALB/c mice.
 
IL-12 therapy is only partially effective in mice neutralized 
for NKG2D
 
IL-12 plays an essential role in the interaction between the
innate and adaptive arms of immunity (28) produced by
APCs and acting on T cells and NK cells to generate cyto-
toxic lymphocytes. IL-12 is also the major cytokine respon-
sible for Th1 cell differentiation, allowing potent production
of IFN-
 
 
 
. Recently, we established that IL-12–mediated an-
timetastatic activity in part via the NKG2D–NKG2D ligand
recognition (24). Because it had been shown that IL-12 ef-
fectively suppressed the development of MCA-induced sar-
comas (29), we next wished to assess whether the efficacy of
IL-12 was NKG2D dependent. WT mice given a lethal dose
of MCA were largely protected by repetitive cycles of IL-12
treatment; however, those mice additionally receiving anti-
NKG2D mAb failed to effectively respond to therapy and
displayed a greater incidence of sarcomas (Fig. 4).
 
Conclusion
 
This is the first report to illustrate the importance of
NKG2D in controlling natural and activated host immunity
to tumor initiation. Previous studies have illustrated the im-
portance of this pathway in the host immune response to s.c.
or i.v. injection of experimental tumors either naturally or
ectopically expressing various NKG2D ligands, but these
studies told us nothing about the role of NKG2D in tumori-
genesis (6, 22–24). In the absence of any NKG2D gene–tar-
geted mouse or, more particularly, a conditional NKG2D
gene–targeted mouse, it is not possible to determine which
effector cell is using NKG2D to control tumor formation.
However, experiments performed here and previously using
the MCA-induced sarcoma model suggest that NK cells, in-
variant NKT cells, and T cells (26, 30, 31) may all play a role
in host response to the initiation of these tumors. Of note,
NKG2D neutralization did not further sensitize WT mice
depleted of NK cells, perforin-deficient mice, or RAG-1
 
   
 
mice deficient in both T cells and B cells. In contrast, the
role of NKG2D was independent of host IFN-
 
 
 
 and TRAIL
effector function, and these data collectively demonstrate
that NKG2D is only one recognition pathway by which ef-
fector lymphocytes control tumor initiation.
We still know relatively little about what controls the ex-
pression of NKG2D ligands in vivo, although various stresses
such as heat, retinoids, carcinogens, and other agents that in-
duce DNA damage may all be effective. The expression of
Rae-1 and H60 was induced by skin painting with the car-
cinogens 7,12-dimethylbenz[
 
a
 
]anthracene (DMBA)/12-
 
O
 
-tet-
radecanoylphorbol 13-acetate (TPA), and the importance
of the NKG2D pathway in host protection from skin carci-
Figure 2. The NKG2D pathway is perforin mediated and only 
partially responsible for host protection from sarcoma by NK cells or 
T cells. (A) Groups of 20 B6 WT or 10 B6 RAG-1    mice were injected s.c. 
in the hind flank with 25  g MCA as indicated. Some WT mice received 
weekly treatments with anti-asGM1 for 8 wk to deplete NK cells. (B) Groups 
of B6 WT mice (n   20) or gene-targeted B6 mice deficient for perforin 
(pfp   ; n   30), TRAIL (n   20), or IFN-  (n   30) were injected s.c. into 
the hind flank with 25  g MCA as indicated. In both A and B, all mice were 
treated i.p. twice weekly from day 0 (the day of MCA inoculation) with 250  g 
of control Ig (cIg) or anti-NKG2D mAb for 8 wk. Palpable sarcomas ( 10 mm2) 
were recorded, and tumor-free mice were monitored for 200 d. The asterisks 
denote a significant effect of anti-NKG2D as determined by Fisher’s exact 
test (P   0.05). 
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noma was implicated but not directly proven (20). The sig-
naling events that are responsible for the up-regulation of
Rae-1 expression on MCA-induced sarcoma tumor cells are
not yet clear, and it will now be important to determine ex-
actly at what stage Rae-1 molecules are expressed after
MCA inoculation. Clearly, NKG2D ligand expression by
Figure 3. Expression of NKG2D ligands indicates immunoediting. 
(A) MCA-induced sarcoma cell lines were derived from various mice and 
assessed for Rae-1 expression as indicated in Materials and methods. Five 
representative sarcoma cell lines derived from WT, TRAIL   , and pfp    
mice (1–5) are shown with Rae-1  Renca renal carcinoma as a positive 
control. Gray lines, isotype control; black lines, Rae-1. (B) Representative 
MCA-induced sarcoma cell lines derived from WT, TRAIL   , and pfp    mice 
were assessed for s.c. growth in groups of five WT or pfp    mice at the 
doses indicated (tumor cell number). As indicated, WT, TRAIL   , and pfp    
sarcoma cell lines were also injected s.c. (105) into groups of five WT mice in 
the presence of control Ig (cIg) or neutralizing anti-NKG2D mAb ( NKG2D). 
Anti-NKG2D and cIg were administered twice weekly i.p. for 3 wk. The data 
is representative of two independent experiments with these tumor lines, 
and four tumors from each strain have been transplanted with similar results. 
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tumor cells may not be a barrier to tumor growth because
many primary tumors and tumor cell lines naturally express
NKG2D ligands, and in some cases these ligands may be se-
creted (32, 33). Direct experimentation has shown that less
tumor rejection occurred when tumors only expressed inter-
mediate levels of Rae-1 (22), so it may be that a threshold
level of ligand expression can be maintained on several tu-
mor cells in the population to effectively down-regulate im-
munity. It now remains to be determined whether NKG2D
plays an important role in other models of tumor immune
surveillance and whether there is some survival advantage for
some tumors to express NKG2D ligands at later stages of tu-
mor development.
 
MATERIALS AND METHODS
 
Mice.
 
Inbred C57BL/6 and BALB/c WT mice were purchased from the
Walter and Eliza Hall Institute of Medical Research. The following gene-
targeted mice were bred at the Peter MacCallum Cancer Centre: C57BL/6
perforin-deficient (B6 pfp
 
   
 
) mice; C57BL/6 TRAIL-deficient (B6
TRAIL
 
   
 
) mice (a gift from J. Peshcon, AMGEN, Seattle, WA) (34); and
C57BL/6 IFN-
 
 
 
–deficient (B6 IFN-
 
 
 
   
 
) mice. All mice that were origi-
nally generated on a 129 background have been backcrossed between 10–
12 times onto the C57BL/6 background. Male mice of 6–12 wk of age
were used in all experiments that were performed according to animal ex-
perimental ethics committee guidelines.
 
MCA-induced sarcoma.
 
Groups of 10–30 male mice were inoculated
s.c. in the right hind leg with 0.1 ml maize oil containing 1–400 
 
 
 
g MCA
(Sigma-Aldrich), and mice were monitored weekly for the development of
fibrosarcoma as previously described (30). The growth of some MCA-
induced fibrosarcomas initiated in B6 and BALB/c or PBS- or IL-12–treated
B6 WT mice was monitored weekly and measured by a caliper square along
the perpendicular axes of the tumors. Palpable tumors 
 
 
 
10 mm
 
2
 
 with pro-
gressive growth for two successive weeks were recorded. Tumor-free mice
did not develop sarcomas beyond 200 d. Some 100-
 
 
 
g MCA-induced sar-
comas that had reached a size of 0.5 cm
 
2
 
 were excised aseptically. Tumors
were cut into small pieces and treated with 1 mg/ml collagenase (type II;
Sigma-Aldrich) and 40 
 
 
 
g/ml DNase I at 37
 
 
 
C for 1 h, clumps were re-
moved, and single cells were cultured in RPMI 1640 with 10% FCS and 2
mM 
 
L
 
-glutamine. The cells were split with 0.1% EDTA when they were
confluent. All tumor cell lines were kept in culture for at least 3 mo to min-
imize cellular contamination. Some sarcoma lines were injected s.c. into
WT or gene-targeted mice as indicated in the figures.
 
IL-12 and anti-NKG2D treatment protocols.
 
Recombinant mouse
IL-12 (Genetics Institute) was suspended in PBS and administrated i.p. as
described previously (35). Groups of mice received 5-d courses of either
PBS or 100 ng IL-12 for 3 wk on and 1 wk off in two 4-wk cycles from the
day of MCA inoculation. Some groups of B6 or BALB/c mice were treated
i.p. with either 250 
 
 
 
g hamster anti–mouse NKG2D mAb (C7 clone) (36)
or 250 
 
 
 
g hamster control Ig mAb twice weekly for 8 wk after tumor inoc-
ulation. It should also be noted that NKG2D
 
 
 
 NK effector cells are not de-
pleted by anti-NKG2D mAb treatment (24). This twice-weekly treatment
regimen completely suppresses NKG2D-mediated rejection of RMA-S–
Rae-1
 
 
 
 tumor cells (Fig. S2, available at http://www.jem.org/cgi/content/
full/jem.20050994/DC1). NK cells were specifically depleted in B6 mice
using 100 
 
 
 
g i.p. rabbit anti-asialo GM1 antibody (Wako Chemicals) on
days 0, 1, and 7 and weekly thereafter for 9 wk (after tumor inoculation) as
described previously (37).
 
Flow cytometric analysis.
 
MCA-induced sarcoma cell lines were de-
rived from various mice and assessed for NKG2D ligand expression as fol-
lows. Staining was performed in PBS with 0.5% BSA and 0.04% sodium
azide on ice using the anti–pan Rae-1–PE or PE-conjugated rat IgG2a iso-
type control. Anti–pan Rae-1 mAb (clone 186107, rat IgG2a isotype; pro-
vided by L. Lanier, University of San Francisco, San Francisco, CA) reacts
with Rae-1
 
 
 
, 
 
 
 
, 
 
 
 
, 
 
 
 
, and 
 
 
 
, as previously described (38). The stained cells
were analyzed on a flow cytometer (LSR II; Becton Dickinson), and the
data were processed using an FCS-Express 2 program (De Novo Software).
 
Statistical analysis. 
 
Significant differences in sarcoma-free mice were
determined by the Fisher’s exact test. P 
 
 
 
 0.05 was considered significant.
 
Online supplemental material. 
 
Fig. S1 shows that anti-NKG2D mAb is
without effect in NK cell– or T cell–deficient mice. Fig. S2 depicts anti-
NKG2D mAb as effectively neutralizing NKG2D. Online supplemental mate-
rial is available at http://www.jem.org/cgi/content/full/jem.20050994/DC1.
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